CRIS Current Research Information System

RIZZO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.472
NA - Nord America 3.460
EU - Europa 2.006
SA - Sud America 226
AF - Africa 206
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.375
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.386
SG - Singapore 1.308
CN - Cina 1.196
VN - Vietnam 907
IT - Italia 518
HK - Hong Kong 340
SE - Svezia 295
DE - Germania 234
KR - Corea 194
GB - Regno Unito 191
BR - Brasile 163
IN - India 152
CH - Svizzera 127
IE - Irlanda 110
FR - Francia 103
NL - Olanda 103
FI - Finlandia 101
BD - Bangladesh 91
RU - Federazione Russa 84
CI - Costa d'Avorio 67
JP - Giappone 48
ID - Indonesia 46
SC - Seychelles 44
CA - Canada 39
PH - Filippine 31
JO - Giordania 30
TG - Togo 26
BG - Bulgaria 25
TR - Turchia 25
ZA - Sudafrica 24
AR - Argentina 23
AT - Austria 23
TH - Thailandia 20
NG - Nigeria 18
MX - Messico 16
PL - Polonia 16
GR - Grecia 14
IQ - Iraq 14
UA - Ucraina 13
ES - Italia 10
PK - Pakistan 10
BE - Belgio 8
EC - Ecuador 8
LT - Lituania 8
CL - Cile 7
CO - Colombia 7
PS - Palestinian Territory 7
TW - Taiwan 7
VE - Venezuela 7
MY - Malesia 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
IR - Iran 5
MA - Marocco 5
PY - Paraguay 5
CR - Costa Rica 4
IL - Israele 4
KE - Kenya 4
AU - Australia 3
CD - Congo 3
HN - Honduras 3
HU - Ungheria 3
KZ - Kazakistan 3
PE - Perù 3
SA - Arabia Saudita 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
TN - Tunisia 3
AZ - Azerbaigian 2
BY - Bielorussia 2
CY - Cipro 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EG - Egitto 2
ET - Etiopia 2
GH - Ghana 2
JM - Giamaica 2
LB - Libano 2
LV - Lettonia 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BO - Bolivia 1
CG - Congo 1
CZ - Repubblica Ceca 1
EE - Estonia 1
FJ - Figi 1
GE - Georgia 1
GT - Guatemala 1
HR - Croazia 1
HT - Haiti 1
KG - Kirghizistan 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 10.366
Salva come PNG Salva come JPEG
Città #
Singapore 903
Hefei 374
Ashburn 373
Hong Kong 318
San Jose 290
Dallas 256
Chandler 226
Ho Chi Minh City 218
Hanoi 207
Seoul 171
Boardman 163
Beijing 158
Santa Clara 148
Council Bluffs 125
Bern 124
Southend 122
Bologna 117
Fairfield 116
Dublin 110
Princeton 107
Dong Ket 96
Los Angeles 88
New York 76
Helsinki 71
Abidjan 67
Lauterbourg 65
Buffalo 48
Houston 47
Redondo Beach 45
Redmond 41
Woodbridge 41
Milan 40
Seattle 39
Guangzhou 37
Frankfurt am Main 36
Haiphong 35
Bengaluru 34
Tokyo 34
Jakarta 33
Wilmington 33
Boydton 31
Amman 30
Cambridge 29
São Paulo 29
Lomé 26
Chicago 25
Da Nang 25
Shanghai 25
Florence 24
London 24
Berlin 23
Lappeenranta 22
Rome 22
Turin 21
Munich 19
Sofia 19
San Diego 17
Shenzhen 16
Nuremberg 15
Biên Hòa 14
Orem 14
Tongling 14
Abeokuta 13
Amsterdam 13
Medford 13
San Francisco 13
Vienna 13
Hải Dương 12
Phoenix 12
Brooklyn 11
Can Tho 11
Castel Maggiore 11
Changsha 11
Istanbul 11
Nanjing 11
Toronto 11
Denver 10
Johannesburg 10
Montreal 10
Zhengzhou 10
Atlanta 9
Des Moines 9
Stockholm 9
Tân Tiến 9
Washington 9
Ann Arbor 8
Brussels 8
Cape Town 8
Hyderabad 8
Madrid 8
Mexico City 8
Olalla 8
Poplar 8
Warsaw 8
Xi'an 8
Charlotte 7
Chennai 7
Chongqing 7
Harbin 7
Jinan 7
Totale 6.482
Salva come PNG Salva come JPEG
Nome #
Adjuvant treatment in biliary tract cancer 345
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 303
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 234
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 229
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 209
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies 208
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 207
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 200
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 197
Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile 194
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma 185
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 180
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements 178
Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma 177
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 169
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 165
Bone targeting agents in patients with metastatic prostate cancer: State of the art 165
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 163
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster 162
Hacking pancreatic cancer: Present and future of personalized medicine 162
The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST) 161
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 160
Skull Metastasis From Uterine Leiomyosarcoma, a Rare Presentation for a Rare Tumor: A Case Report and Review of the Literature 158
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 152
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? 149
Third-and later-line treatment in advanced or metastatic gastric cancer: A systematic review and meta-analysis 148
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma 142
Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review 141
Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis 140
Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis 140
Genomics and Immunomics in the Treatment of Urothelial Carcinoma 135
Experimental HER2- targeted therapies for biliary tract cancer 128
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures 128
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors 122
Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions 114
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges 111
Novel HER2-directed treatments in advanced gastric carcinoma: Another paradigm shift? 111
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials 109
Metabolomic profiling in renal cell carcinoma patients: News and views 108
Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer 108
Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report 108
The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy Among Patients with Urothelial Carcinoma: A Meta-Analysis 103
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study 103
Hypothesis on the possible relevance of the immunogenic cell death in the treatment of gestational trophoblastic neoplasms 98
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents 97
Combination therapy of dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer 91
Recurrent Uterine Smooth-Muscle Tumors of Uncertain Malignant Potential (STUMP): State of The Art 90
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue 87
Cancer immunotherapy: Current and future perspectives on a therapeutic revolution 84
Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma 84
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 84
First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: “And Yet It Moves!” 83
Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis 80
Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives 78
Second-line FOLFOX chemotherapy for advanced biliary tract cancer 78
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis 76
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer 76
BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care 75
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis 73
Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis 73
Microbiota and prostate cancer 72
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? 70
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives 70
TRK inhibition in cholangiocarcinoma: Trying to teach an old dog new tricks 70
Cabozantinib for Treatment of Brain Metastases in Patients with Renal Cell Carcinoma 68
The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): A new Pandora's box? 65
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma 64
Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: A meta-analysis 63
Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis 62
The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: Will immunotherapy solve the problem? 59
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? 59
Atezolizumab in advanced hepatocellular carcinoma: Good things come to those who wait 59
Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand? 58
Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis 56
Novel targeted therapies for advanced cholangiocarcinoma 55
Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: A meta-analysis 54
Precision oncology in cholangiocarcinoma: current issues in clinical trial design and access to targeted therapies 54
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma 53
Recent advances of immunotherapy for biliary tract cancer 52
DNA damage response alterations in gastric cancer: Knocking down a new wall 51
In Regard to “A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)” 49
Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis 47
Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma 46
Systemic adjuvant treatment in hepatocellular carcinoma: Tempted to do something rather than nothing 45
Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis 44
Toward personalized therapy for cholangiocarcinoma: new insights and challenges 44
A brand-new CAR for macrophages: Is it time to fire up the engines of a new era for the treatment of renal cell carcinoma? 43
Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer 43
Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis 42
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: A critical overview of recent evidence 39
Advances in Novel Systemic Therapies for Advanced Hepatocellular Carcinoma 39
Regarding “HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer” 39
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma 37
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma 37
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials 36
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study 35
Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma 31
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study 30
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma 30
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study 29
Totale 10.417
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.131
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.131
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021121 0 0 0 0 0 0 0 0 0 0 0 121
2021/2022756 41 11 23 42 39 17 16 50 173 54 183 107
2022/20231.462 97 132 60 106 148 163 63 92 223 66 107 205
2023/2024417 67 71 32 29 25 65 14 22 15 36 20 21
2024/20252.011 85 251 232 141 231 87 147 88 32 112 191 414
2025/20265.505 476 546 715 423 476 241 519 250 908 444 295 212
Totale 10.650